Flurbiprofen Axetil as an Adjuvant to Pre-emptive Scalp Infiltration
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
Post-craniotomy pain remains a major challenge in patient care following
neurosurgery.Flurbiprofen axetil (FA), as an injectable nonselective cyclooxygenase
inhibitor, is a widely prescribed NSAID for postoperative pain. As FA is highly lipophilic by
merging into emulsified lipid microspheres, it has a high affinity to the surgical incision
and inflammatory tissues to achieve targeted drug therapy and prolonged duration of action,
thus providing a basis for its local use to achieve efficacy and safety comparable to or
greater than systemic administration. In this study, we attempt to evaluate the clinical
effects of FA as an adjunct to ropivacaine in pre-emptive scalp infiltration to prevent or
reduce pain after craniotomy.